Aldeyra Therapeutics (ALDX) Expected to Post Quarterly Earnings on Thursday

Aldeyra Therapeutics (NASDAQ:ALDX) will likely be releasing its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to post earnings of ($0.11) per share and revenue of $31.33 million for the quarter. Investors can check the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Friday, August 7, 2026 at 4:00 PM ET.

Aldeyra Therapeutics (NASDAQ:ALDX) last announced its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.07. On average, analysts expect Aldeyra Therapeutics to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Aldeyra Therapeutics Stock Performance

Shares of Aldeyra Therapeutics stock opened at $1.61 on Thursday. Aldeyra Therapeutics has a 52-week low of $1.07 and a 52-week high of $6.17. The company has a fifty day moving average of $1.84 and a 200-day moving average of $2.85. The stock has a market capitalization of $97.12 million, a price-to-earnings ratio of -3.50 and a beta of 1.16.

Wall Street Analyst Weigh In

ALDX has been the subject of several recent research reports. Wall Street Zen raised shares of Aldeyra Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, June 6th. Weiss Ratings cut Aldeyra Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, May 20th. One equities research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Aldeyra Therapeutics has an average rating of “Hold” and an average price target of $5.50.

Insiders Place Their Bets

In related news, CEO Todd C. Brady acquired 250,000 shares of the company’s stock in a transaction dated Wednesday, June 3rd. The stock was purchased at an average price of $1.67 per share, with a total value of $417,500.00. Following the completion of the purchase, the chief executive officer owned 1,721,298 shares in the company, valued at $2,874,567.66. This trade represents a 16.99% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 11.80% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. AQR Capital Management LLC raised its holdings in Aldeyra Therapeutics by 275.4% during the 2nd quarter. AQR Capital Management LLC now owns 1,473,812 shares of the biotechnology company’s stock valued at $5,645,000 after buying an additional 1,081,257 shares during the last quarter. Kennedy Capital Management LLC grew its holdings in Aldeyra Therapeutics by 61.9% in the 3rd quarter. Kennedy Capital Management LLC now owns 1,112,213 shares of the biotechnology company’s stock worth $5,806,000 after acquiring an additional 425,245 shares during the last quarter. Bank of America Corp DE grew its holdings in Aldeyra Therapeutics by 590.5% in the 3rd quarter. Bank of America Corp DE now owns 390,078 shares of the biotechnology company’s stock worth $2,036,000 after acquiring an additional 333,587 shares during the last quarter. Jacobs Levy Equity Management Inc. increased its position in shares of Aldeyra Therapeutics by 49.4% in the third quarter. Jacobs Levy Equity Management Inc. now owns 947,551 shares of the biotechnology company’s stock valued at $4,946,000 after acquiring an additional 313,395 shares during the period. Finally, Two Sigma Investments LP increased its position in shares of Aldeyra Therapeutics by 389.9% in the third quarter. Two Sigma Investments LP now owns 273,054 shares of the biotechnology company’s stock valued at $1,425,000 after acquiring an additional 217,315 shares during the period. 59.71% of the stock is owned by hedge funds and other institutional investors.

About Aldeyra Therapeutics

Aldeyra Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapies for immune-mediated diseases. The company’s research efforts center on targeted alkenals, a class of reactive aldehyde species that play a key role in inflammatory pathways. By selectively modulating these pathways, Aldeyra aims to address both ocular and systemic indications with high unmet medical need.

The company’s lead product candidate, reproxalap, is being investigated in several ophthalmic disorders, including dry eye disease, allergic conjunctivitis and non-infectious anterior uveitis.